Compass Therapeutics (CMPX) Other Non-Current Assets (2019 - 2026)
Compass Therapeutics recorded quarterly Other Non-Current Assets of $568000.0 in Q1 2026, little changed quarter-over-quarter from $568000.0 in Q4 2025, and little changed year-over-year from $568000.0 in Q1 2025.
Compass Therapeutics' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $568000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $568000.0; the TTM figure through Mar 2026 stood at $568000.0 (changed 0.0% YoY), while the FY2025 annual figure was $568000.0, changed 0.0% from the prior year.
- Other Non-Current Assets came in at $568000.0 for Q1 2026 at Compass Therapeutics, roughly flat from $568000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $568000.0 in Q3 2024 to a low of $320000.0 in Q1 2022.
- A 5-year average of $422117.6 and a median of $320000.0 in 2022 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets changed 0.0% in 2022 and surged 77.5% in 2024, its largest moves.
- Compass Therapeutics' Other Non-Current Assets stood at $320000.0 in 2022, then changed by 0.0% to $320000.0 in 2023, then jumped by 77.5% to $568000.0 in 2024, then changed by 0.0% to $568000.0 in 2025, then changed by 0.0% to $568000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $568000.0, $568000.0, and $568000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | 568,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 568,000.00 |
| Dec 31, 2025 | 568,000.00 |
| Sep 30, 2025 | 568,000.00 |
| Jun 30, 2025 | 568,000.00 |
| Mar 31, 2025 | 568,000.00 |
| Dec 31, 2024 | 568,000.00 |
| Sep 30, 2024 | 568,000.00 |
| Jun 30, 2024 | 320,000.00 |
| Mar 31, 2024 | 320,000.00 |
| Dec 31, 2023 | 320,000.00 |
| Sep 30, 2023 | 320,000.00 |
| Jun 30, 2023 | 320,000.00 |
| Mar 31, 2023 | 320,000.00 |
| Dec 31, 2022 | 320,000.00 |
| Sep 30, 2022 | 320,000.00 |
| Jun 30, 2022 | 320,000.00 |
| Mar 31, 2022 | 320,000.00 |
| Dec 31, 2021 | 320,000.00 |
| Sep 30, 2021 | 210,000.00 |
| Mar 31, 2021 | 320,000.00 |
| Dec 31, 2020 | 320,000.00 |
| Sep 30, 2020 | 263,000.00 |
| Jun 30, 2020 | 69,000.00 |
| Dec 31, 2019 | 200,000.00 |